Counterfeit medicines: relevance, consequences and strategies to combat the global crisis
Autor(a) principal: | |
---|---|
Data de Publicação: | 2023 |
Outros Autores: | |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Brazilian Journal of Pharmaceutical Sciences |
Texto Completo: | https://www.revistas.usp.br/bjps/article/view/210594 |
Resumo: | Counterfeiting of medicines, also known as “falsification” or “adulteration”, is the process in which the identity, origin, or history of genuine medicines are intentionally modified. Currently, counterfeit medicines are a global crisis that affects and is mostly caused by developing countries in Asia, Africa and Latin America. These countries lack strict law enforcement against this practice and have low-income populations with medicinal needs. Lately, the crisis has escalated, impacting developed countries as well, e.g., the US and the EU, mainly via the Internet. Despite this extension, some current laws aim to control and minimize the crisis’ magnitude. Falsification of medicines maintains an illegitimate supply chain that is connected to the legitimate one, both of which are extremely complex, making such falsification difficult to control. Furthermore, political and economic causes are related to the crisis’ hasty growth, causing serious consequences for individuals and public health, as well as for the economy of different countries. Recently, organizations, technologies and initiatives have been created to overcome the situation. Nevertheless, the development of more effective measures that could aggregate all the existing strategies into a large functioning network could help prevent the acquisition of counterfeit medicines and create awareness among the general population. |
id |
USP-31_b15b3397de72672e7d3bee66f7459259 |
---|---|
oai_identifier_str |
oai:revistas.usp.br:article/210594 |
network_acronym_str |
USP-31 |
network_name_str |
Brazilian Journal of Pharmaceutical Sciences |
repository_id_str |
|
spelling |
Counterfeit medicines: relevance, consequences and strategies to combat the global crisisCounterfeit medicinesFalsificationLegislationMedicines supply chainBrazilCounterfeiting of medicines, also known as “falsification” or “adulteration”, is the process in which the identity, origin, or history of genuine medicines are intentionally modified. Currently, counterfeit medicines are a global crisis that affects and is mostly caused by developing countries in Asia, Africa and Latin America. These countries lack strict law enforcement against this practice and have low-income populations with medicinal needs. Lately, the crisis has escalated, impacting developed countries as well, e.g., the US and the EU, mainly via the Internet. Despite this extension, some current laws aim to control and minimize the crisis’ magnitude. Falsification of medicines maintains an illegitimate supply chain that is connected to the legitimate one, both of which are extremely complex, making such falsification difficult to control. Furthermore, political and economic causes are related to the crisis’ hasty growth, causing serious consequences for individuals and public health, as well as for the economy of different countries. Recently, organizations, technologies and initiatives have been created to overcome the situation. Nevertheless, the development of more effective measures that could aggregate all the existing strategies into a large functioning network could help prevent the acquisition of counterfeit medicines and create awareness among the general population.Universidade de São Paulo. Faculdade de Ciências Farmacêuticas2023-04-14info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://www.revistas.usp.br/bjps/article/view/21059410.1590/s2175-97902023e20402Brazilian Journal of Pharmaceutical Sciences; Vol. 59 (2023); e20402 Brazilian Journal of Pharmaceutical Sciences; v. 59 (2023); e20402 Brazilian Journal of Pharmaceutical Sciences; Vol. 59 (2023); e20402 2175-97901984-8250reponame:Brazilian Journal of Pharmaceutical Sciencesinstname:Universidade de São Paulo (USP)instacron:USPenghttps://www.revistas.usp.br/bjps/article/view/210594/194409Copyright (c) 2023 Brazilian Journal of Pharmaceutical Scienceshttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessBittar Araujo Lima, MarcelaYonamine, Mauricio2023-05-24T18:28:32Zoai:revistas.usp.br:article/210594Revistahttps://www.revistas.usp.br/bjps/indexPUBhttps://old.scielo.br/oai/scielo-oai.phpbjps@usp.br||elizabeth.igne@gmail.com2175-97901984-8250opendoar:2023-05-24T18:28:32Brazilian Journal of Pharmaceutical Sciences - Universidade de São Paulo (USP)false |
dc.title.none.fl_str_mv |
Counterfeit medicines: relevance, consequences and strategies to combat the global crisis |
title |
Counterfeit medicines: relevance, consequences and strategies to combat the global crisis |
spellingShingle |
Counterfeit medicines: relevance, consequences and strategies to combat the global crisis Bittar Araujo Lima, Marcela Counterfeit medicines Falsification Legislation Medicines supply chain Brazil |
title_short |
Counterfeit medicines: relevance, consequences and strategies to combat the global crisis |
title_full |
Counterfeit medicines: relevance, consequences and strategies to combat the global crisis |
title_fullStr |
Counterfeit medicines: relevance, consequences and strategies to combat the global crisis |
title_full_unstemmed |
Counterfeit medicines: relevance, consequences and strategies to combat the global crisis |
title_sort |
Counterfeit medicines: relevance, consequences and strategies to combat the global crisis |
author |
Bittar Araujo Lima, Marcela |
author_facet |
Bittar Araujo Lima, Marcela Yonamine, Mauricio |
author_role |
author |
author2 |
Yonamine, Mauricio |
author2_role |
author |
dc.contributor.author.fl_str_mv |
Bittar Araujo Lima, Marcela Yonamine, Mauricio |
dc.subject.por.fl_str_mv |
Counterfeit medicines Falsification Legislation Medicines supply chain Brazil |
topic |
Counterfeit medicines Falsification Legislation Medicines supply chain Brazil |
description |
Counterfeiting of medicines, also known as “falsification” or “adulteration”, is the process in which the identity, origin, or history of genuine medicines are intentionally modified. Currently, counterfeit medicines are a global crisis that affects and is mostly caused by developing countries in Asia, Africa and Latin America. These countries lack strict law enforcement against this practice and have low-income populations with medicinal needs. Lately, the crisis has escalated, impacting developed countries as well, e.g., the US and the EU, mainly via the Internet. Despite this extension, some current laws aim to control and minimize the crisis’ magnitude. Falsification of medicines maintains an illegitimate supply chain that is connected to the legitimate one, both of which are extremely complex, making such falsification difficult to control. Furthermore, political and economic causes are related to the crisis’ hasty growth, causing serious consequences for individuals and public health, as well as for the economy of different countries. Recently, organizations, technologies and initiatives have been created to overcome the situation. Nevertheless, the development of more effective measures that could aggregate all the existing strategies into a large functioning network could help prevent the acquisition of counterfeit medicines and create awareness among the general population. |
publishDate |
2023 |
dc.date.none.fl_str_mv |
2023-04-14 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://www.revistas.usp.br/bjps/article/view/210594 10.1590/s2175-97902023e20402 |
url |
https://www.revistas.usp.br/bjps/article/view/210594 |
identifier_str_mv |
10.1590/s2175-97902023e20402 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
https://www.revistas.usp.br/bjps/article/view/210594/194409 |
dc.rights.driver.fl_str_mv |
Copyright (c) 2023 Brazilian Journal of Pharmaceutical Sciences https://creativecommons.org/licenses/by/4.0 info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Copyright (c) 2023 Brazilian Journal of Pharmaceutical Sciences https://creativecommons.org/licenses/by/4.0 |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Universidade de São Paulo. Faculdade de Ciências Farmacêuticas |
publisher.none.fl_str_mv |
Universidade de São Paulo. Faculdade de Ciências Farmacêuticas |
dc.source.none.fl_str_mv |
Brazilian Journal of Pharmaceutical Sciences; Vol. 59 (2023); e20402 Brazilian Journal of Pharmaceutical Sciences; v. 59 (2023); e20402 Brazilian Journal of Pharmaceutical Sciences; Vol. 59 (2023); e20402 2175-9790 1984-8250 reponame:Brazilian Journal of Pharmaceutical Sciences instname:Universidade de São Paulo (USP) instacron:USP |
instname_str |
Universidade de São Paulo (USP) |
instacron_str |
USP |
institution |
USP |
reponame_str |
Brazilian Journal of Pharmaceutical Sciences |
collection |
Brazilian Journal of Pharmaceutical Sciences |
repository.name.fl_str_mv |
Brazilian Journal of Pharmaceutical Sciences - Universidade de São Paulo (USP) |
repository.mail.fl_str_mv |
bjps@usp.br||elizabeth.igne@gmail.com |
_version_ |
1800222917654478848 |